drugset

drugset / Trial / NCT05787418

HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2

NCT05787418 ↗

Phase 3 Enrolling by invitation 1200 enrolled Huahui Health

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study will assess the efficacy of HH-120 nasal spray in participants for the post-exposure prevention of SARS-CoV-2.

Timeline

Start: 2023-03-31
Primary completion: 2025-12-31
Completion: 2026-04-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HH-120 Nasal Spray	Unknown	—	Intranasal

Indications